| Generic Name |
Brand Name |
Breast cancer type |
Breast cancer stage |
Where in the drug approval process is this treatment |
| Pegylated Liposomal Doxorubicin |
Caelyx |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Health Canada - Approved |
| Pembrolizumab |
Keytruda |
Triple Negative |
Stage IV (metastatic) |
PCPA - Approved; Provincial Review Ongoing |
| Pembrolizumab |
Keytruda |
Triple Negative |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
| Pembrolizumab |
Keytruda |
Gene mutation |
Stage IV (metastatic) |
CDA - Under Review |
| Pertuzumab |
Perjeta |
HER2+ |
Stage Ib, II, III |
Listed on Provincial Drug Formulary |
| Pertuzumab |
Perjeta |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Pertuzumab, Trastuzumab & hyaluronidase-zzxf subcutaneous |
PHESGO (Perjeta, Herceptin & hyaluronidase-zzxf subcutaneous) |
HER2+ |
Stage Ib, II, III |
Health Canada - Approved |
| Pertuzumab, Trastuzumab & hyaluronidase-zzxf subcutaneous |
PHESGO (Perjeta, Herceptin & hyaluronidase-zzxf subcutaneous) |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Ribociclib (plus an aromatase inhibitor) |
Kisqali (plus an aromatase inhibitor) |
HR+, HER2- |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Ribociclib (plus aromatase inhibitor) |
Kisquali (plus an aromatase inhibitor) |
HR+, HER2- |
Stage Ib, II, III |
CDA - Under Review |
| Ribociclib (plus fulvestrant) |
Kisqali (plus fulvestrant) |
HR+, HER2- |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Sacituzumab govitecan |
Trodelvy |
Triple Negative |
Stage IV (metastatic) |
PCPA - Approved; Provincial Review Ongoing |
| Sacituzumab govitecan |
Trodelvy |
HR+, HER2- |
Stage IV (metastatic) |
PCPA - Approved; Provincial Review Ongoing |
| Tamoxifen |
Nolvadex; various brand names |
HR+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Temozolomide |
Temodal; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab |
Herceptin |
HER2+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab biosimilar |
Herzuma (biosimilar) |
HER2+ |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
| Trastuzumab biosimilar |
Herzuma (biosimilar) |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab biosimilar |
Ontruzant (biosimilar) |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab biosimilar |
Kanjinti (biosimilar) |
HER2+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab biosimilar |
Ogivri (biosimilar) |
HER2+ |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
| Trastuzumab biosimilar |
Trazimera (biosimilar) |
HER2+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
HER2-ultra low |
Stage IV (metastatic) |
CDA - Under Review |
| Trastuzumab deruxtecan |
Enhertu |
HER2-low |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
HER2+ |
Stage Ib, II, III |
Listed on Provincial Drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Trastuzumab Subcutaneous |
Herceptin SC |
HER2+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Health Canada - Approved |
| Trastuzumsab biosimilar (with pertuzumab and a taxane) |
Ogivri |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Tucatinib |
Tukysa |
HER2+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
| Vinorelbine |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |